Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions

Infectious Diseases

Answer 3
  1. Administration of pegylated interferon alfa. Administration of ribavirin causes erythrocyte hemolysis to a variable degree in most patients. Therefore, ribavirin is contraindicated in patients with anemia, hemolysis, and hemoglobinopathies. Ribavirin is excreted by the kidneys; thus, patients with renal disease (ie, serum creatinine > 2.0 mg/dL) can develop severe hemolysis. Monotherapy with pegylated interferon alfa is preferred in situations in which therapy with ribavirin is contraindicated.1,2

     Chronic hepatitis C: current disease management. Bethesda (MD): National Digestive Diseases Information Clearinghouse; 2002. NIH Publication No. 02-4230. Available at http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm. Accessed 2 Dec 2002.

    2. Management of hepatitis C: 2002. National Institutes of Health Consensus
    Development Conference Statement; 2002 Jun 10-12; Bethesda, MD. Available at http://consensus.nih.gov/cons/116/116cdc_intro.htm. Accessed 2 Dec 2002.

Click here to return to the questions


Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj